Revised IDE guidance articulates investigational device "compassionate use" policy.
This article was originally published in The Gray Sheet
REVISED IDE GUIDANCE ARTICULATES "COMPASSIONATE USE" POLICY, allowing for use of investigational or unapproved devices outside of an investigational device exemption for patients with serious conditions. The final guidance, dated Jan. 20, sets in writing FDA's informal policy of approving IDE supplements for "compassionate use" of a device on an individual or small group of patients with a serious, but not life-threatening, condition. FDA handles a few requests each year for compassionate use approval.
You may also be interested in...
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.